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SummαηMice orally infected Campylobacter jejuni developed focal infiltrative 
necrotic lesions in the liver， as determined by both histology and liver function tests. 
Histopathological feature of the liver， a focal infiltrative necrosis， was seen between days 
30 and 60 postinoculation， and it became gradual1y more profound with time， despite the 
fact that liver functions of infected mice were most affected at 2 months postinoculation. 
The capacity of C. jejuni to induce hepatic lesions seemed to be related to that of organisms 
to persist in the gall bladdar. Hepatic lesions following C. jejuni infection was attributable 
to the hepatotoxic factor which was isolated from the subcellular components of bacteria 
by two series of chromatographic separations. This factor was able to induce hepatitis 
after it was injected intravenously into mice at a dose of 10μg. Hepatotoxic activity of this 
factor was confirmed by incubating several doses of this factor with mouse hepatocytes : at 
low concentrations ( < 5μg/mI) hepatocytes became rounding-up， while at high concentra国
tions (>20μg/mI) they exhibited cytolytic changes. Among 20 clinical isolates of C. jejuni， 
only four strains evoked hepatitis in mice and produced the hepatotoxic factor. 
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緒 宝昔Eヨ
染も臨床像から確認され，肝炎や関節炎の発症を認めた
臨床報告がなされている (3).C. jejuniによる enteritis
Campylobacter jefus subsp目 jejuni(C. jejuni)は，感 の発症には Vibriocholeraeや enterotoxigenicEs-
染性腸炎の起因菌として分離頻度の高い細菌の一つであ cherich勿 coliの産出する enterotoxin(ET)と共通抗




る(1， 2). 一方，肝炎や関節炎の発症もある種の HLA型と関連















2. 使用菌株:Campylobacer jejuni GIFU 8734 (血
清型:PEN 18)及び当教室において分離・同定した臨床
株20株を用いた〔詳細については表5に記載).
3. 菌の培養目 gelatindisc (11)にて-80'Cに保存
した菌株を37'cで trypticsoy broth (BBL Microbiol-
ogy systems) 1 mlにて溶解した後，溶解液の一部を10
%馬血液含有の Brucel1aagar (Difco)に塗抹し， 42'C 
で24時間嫌気ジャー内で Gas-Pak(触媒無し， BBL)を
用いて培養した.寒天培地上に生育した菌の一部を液体
培地 (2%w/v tryptose， 0.2% w/v KzHP04， 0.6% w 
/v NaCl， 1% w/v soluble starch， 0.02% w/v L-
cyst巴ine，1% w/v yeast extract， 0.01% w/v sodium 
bicarbonat巴〕に接種し，平板培地の時と同環境下で48時
間培養した.





投与後 7日毎に一ヵ月間マウスの r巴tro-orbitalvenous 
plexusより採血し，血清を分離じた後肝機能検査を行な
った.同時に肝臓・胆のう・腸管を摘出し以下の如く菌







-saline (10μg / ml vancomycin， 2“5 IU/ml polymixin 
B， 5f.1-g / ml trimethoprim含有〉で腸内容物を洗浄後，






mM  MgCI2， 1μ:g/ml DNas巴type1 (Sigma社)，及び
0.05% sodium dod巴cylsulphat巴(SDS)含有の10mM
Tris-HCl (pH7.2)に懸濁し，超音波破砕器(海上電機
社〉で20分間 (platecurrent : 300 mA)菌体破砕を行な












濁した後，同 bufferで平衡化した Sephorose4B (Phar 









Hanks' blanced salt solution (HBSS，フェノールレッ
ド不合〕で十分透析した後，肝細胞に対する毒性を検定
した.
6. 肝細胞培養.マウス肝細胞を Berry& Friend 
(12)らの方法に従い collagenas巴P巴rfusion法により分
離した.麻酔下で開腹したマウスの肝臓を50mlの
Ca2+， Mg2+不合の Hanks氏液 (CMFS)で潅流後，
100 mlの0.05%col1agenase (type IV， Sigma社)， 0.1 
% bovine serum albumin及び 4mMCaCl2含有
CMFSで潅流した.潅流液は全て使用前に37'Cで保温
し， 95% 0，・ 5%C02混合ガスを30分間通気させたもの
を使用した.
2回目の潅流後肝臓全体を摘出し， coldCMFSですす
いだ後， cold CMFS 50 ml入りのピーカーに入れ，周









トプレート CFalcon3047， Nippon Becton， Dickinson 
Co.， Ltd. Tokyo J apan)にまき，さらtこ500μJのWil-





7. 肝細胞障害試験 C.jejuni より分離した標品50







尚，培養上清中の GOTは Henl巴y& Pollard (13) 
らの方法で， LDHはWrobl巴wski& Ladue (14) らの
方法にて行い， 1. 9 mlの反応系に0.1mlの培養上清を
加え， 340nmにおける吸光度の変化を測定した.





9. 肝機能検査.マウス血清中の GOT (glutamic-
oxaloacetic transaminase)， GPT (glutamic-pyruvic 
transaminase)， ALP (alkaline phosphatas巴〕及び
LDH Oactic d巴hydrogenase)について測定した.GOT， 
GPTはKarmenらの方法 (15)，ALPはKind&King






C. jejuni GIFU 8734株 106 cfuを経口投与後 1，

















一ヶ月目に有意の上昇を認めた (Table 2). GPT は
GOTより少し遅れて上昇する傾向があり， GOT，LDH固
Table 1. Quantitative recovery of C. jejuni in mice 
after oral inoculation of strain GIFU 
Viable counts [log，o (cfu per gr tissue) J 
Site Days 乱10nths
3 5 7 l 2 3 4 5 6 
Small intestine 7.6 6.2 5.3 5目2 4.8 4.5 3.6 4.6 3.2 2.3 
Caecum 3.8 3.4 2.5 2.0 2.6 2.0 l.2 l.0 l.0 
Colon 3.3 4.0 3.4 3.2 l.7 
Liver l.0 1目4 3.4 3.3 2.6 2.3 2.2 
Gall bladder l.5 l.8 2.0 3.5 2.8 2.5 2.7 l.6 
Mice wer orally infected with 106 cfu. At intervals eight mice were killed and the intestines and organs processed (see 
Methods) to obtain colony counts. The figures represent the mean values for巴ightmice at each sampling time， -， No 








Fig. 1. Hitological changes in th巴 liv巴rof mic巴 ora11yinfect巴d
with C. j匂iuniGIFU 8745. a) Inflammatory c巴1infiltrate 
in the vicinity of the central vein at 2 weeks postinfection 
b) Focal ce11ular changes of th巴 parenchymaat 1 month 
postinfection. c) Increased int巴nsity of infiltrative 
changes at 3 months postinfection. d) Formation of focal 
infiltrative necrosis in the paranchyma at 6 months postin-
fection. e) Control liver of the uninf巴cted10-month-old 



































は， 100μg/ml でのみ認められた• E. coliのP65回分
では仇 vitroにおける肝細胞障害性は認められなかった.
P65画分を Sepharose4Bによるゲノレ穏過を行なったと
ころ， void volum巴より少し遅れて溶出される 280nm
のピークに一致して肝細胞障害性が認められ (Fig.3-a)
たので， この画分をプーノレし DEAE-SepharoseCL-6B 
Table 2. Liver function tests in mic巴 oral1yinoculated 




1 2  4 
GOT l30士21 150士18 110土16 100土24 100十13 95土12
GPT 50土6 80土12 90土16 130士14 75士9 38土 6
ALP 24.8士l.5 18.9士2.7 16.4土18 15.6土2.0 14.3士l.7 13.2士2.4
LDH 400土21 450士32 380士18 300土24 275土32 200士16
Albumin 4.5士0.8 4.0土0.4 3.0土0.3 2.8土0.2 2.6土0.1 2.4土0.2
Albumin/globulin l.4土0.2 l.1士0.3 0.9:t0.2 0.7士0.2 目6士0.1 0.4士0.2
Data ware obtained from four mice and are expressed as the mean of four samples土 SD. GOT， GPT and LDH are 
expr巴ssedin IU L-" ALP in LAU and serum albumin in mg L- 1 • 
Mean control values; GOT (58.9)， GPT (30.3)， ALP (15.9)， LDH (123.0)， Albumin (5.0)， Albumin / globulin (l.9) 
Samplesa 
P65 of C. jejz抑制
P65 of E. coli 
Medium control 
Table 3. Enzyme leakag巴 andalbumin synthesis in cultures of mous巴
hepatocytes incubated with P65 pr巴rarations
D~e Released enzymes (rn U / m]) 
(，ug/m]) GOT LDH 
10 14土3(P<O.I)b 26士 7(P<O.I) 
50 24土8(P<0.05) 57士 o(P<0.05) 
100 59士7(Pく0.01) 116土10(Pく0.01)
50 6土3 19土 5










a. The hepatocytes were cultured with the doses of samles indicated for 24 h. Each culture was done in triplicate and 
data were obtained from three different experiments. The results ar巴expr巴s巴das the mean士 SDfor the nine 
cultures 
b. The levels of significance for the observed frequencies， compared to the controls， were determined by Student's t-test 
Campylobacter jejuniの肝障害性に関する研究 (223) 
に吸着させ， 0.05-0.8 M NaClの直線的濃度勾配下で
吸着物質の溶出を行なった (Fig.3-b). 非吸着画分
(A)， O.lM NaCl溶出画分 (B)，0.3M NaCl溶出画
分 (C)，0.5M NaCl溶出国分(D)の 4つの画分を得













control '0 50 100 150 200 
Concentrations of p65 (ドg/mouse) 
Fig. 2. Liver function in mice injected with the 
P65 fraction from C. jejuni GIFU 8734 ( 
亡コ)or E. coli 271-6 (・圃).Groups of 
five mice were injected intravenously with 
indicated doses of P65 material and bled at 
five days post-injection. Data were 
obtained from two separat巴巴xperim巴nts
































Table 4. Enzyme leakage and albumin synthesis by cultures of mouse 
hepatocytes following incubation with hepatotoxic factor(s) 
Samples' 
Released enzymes (mU/mJ) Albumin synthesis 
GOT LDH (μg/mJ) 
Cjりunz
P65 (10μg/mJ) 15土2(P<O.l)b 27士 5(Pく0.1) 2.1士0.2
Peak A (10μg/mJ) 7土1 15土 3 2.2土0.3
Peak B (10μg/mJ) 7士2 17士 2 2.1士0.1
Peak C (10μg/mJ) 70:13 (Pく0.01) 164土15(P<O.OI) 1.2土0.2(P<0.05) 
Peak D (10μg/mJ) 8土3 17土 3 2.2:t0.2 
Control 
Medium 7:11 16士 2 2.3土0.2
a. Hepatocytes were cultured with the doses of samples indicated for 24 h. Each cultute was grown in triplicate and 
data were obtained from three different experiments. Results are expressed as the mean土 SDfor the nine 
cultures. 































































Fig. 3. Chromatographic separation of hepatotoxic factor(s). (a) P65 material from 
C. jejuni GIFU 8734 was chroratographed on Sepharos巴 4B. (・-・)optical 
density at 280 nm， (・・・)% cytotoxicity : V 0 ; void volume. (b) The second 
peak obtained during Sepharos巴 4Bchromatography was applied to a column 
of DEAE-Sepharos巴 4Band eluted with an incr巴asingN aCl gradient. . ; 
initiation of gradient elution 
600 550 500 300 350 400 叫50
Elution volumes (ml) 
50 。
























次に肝内定着株8株から P65画分を調整し，in vivo 
における肝炎誘発能及び invitroの肝細胞培養系での肝
細胞障害性を判定した (Table6). 
































Conce円trationso( peak C (mg/LI 
Fig. 4. Hepatotoxicity of peak C. Mouse Hepatocytes w巴recultured with graded doses 
。fpeak C material for 24 h. GOT 1巴akagein the supernatant fluid and cytotox. 
icity of hepatocytes were assayed for triplicate cultures. Data w巴reobtained from 
thr巴es巴parate巴xperiments，and expressed as the mean士 SDfor the 15 cultures : 
〔ー)% Cytotoxicity， (仁コ)GOT (mU/mI) 
~O 9日.1
Source detalis and pathogenicity of the 































































































Groups of five mice were infected orally with 10' cfu of each strain and bled 30 days post-infection 
十 morethan four mice per group， carrying 1，000 cfu/ gr intestinal tissue. 
十 mor巴thanfour mice per group， carrying 1，000 cfu/ gr liver tissue. 









Fig. 5. Morphological changes of mouse hepatocytes cultured for 
24 h with p巴akC. a) 5μg/ml of peak C， b) 20μg/ml 
of p巴akC， c) control cultur巴sCMagnification x 125). 
Fig. 7. Histological chang巴sin the liver of mice intravenously 
injected with 10μg of peak C. a) 48 h after injection， b) 















































































6 8 10 12 30 4 6 8 10 '2 
Days after injection Days after infection 
Fig. 6. Liver function tests in mice intravenously inj巴ctedwith 10μg of p巴akC material. Each group 
consisted of three mic巴ateach time point. Results and expr巴ssedas the m巴anof three 
samples :t SD. GOT， GPT， and LDH are expressed in IU/L and ALP in KAU. Data are for; 
(0) mice inj巴ctedwith peak C mat巴rial(10μg) ; (・)mice inj巴ctedwith LPS from C. jejuni 


























H巴patotoxicityof P65 fractions 
prepared from eight strains of C. 
jejuni capable of colonsing the liver 
Serum巴nzymes(IU /L) b % Cyto_C 







































Groups of five mice were injected intra百 nously
with 100μg of P65 fraction prepared from each test 
strain 
Mice were bled five days post-injection and the 
levels of GOT and LDH in the serum were mea 
sured. Data were obtained from two separates 
experiments and ar巴expressedas the mean土 SD
Control levels of GOT and LDH were 52士 11IU/L 
and 110 :t 14 IU/L， r巴spectively.
Cytotoxicity was assayed by the exclusion of trypan 
blue after a 24-h culture of mouse hepatocytes with 
75 mg/L of P65 material. Data are expressed as the 
mean士 SD for seven cultures. Control samples 
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